Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

NCT00719966 ·Status: COMPLETED

Fasting-mimicking Diet Intervention on Side Effects of Aromatase Inhibitors Treatment in Patients With Breast Cancer

NCT06610565 ·Status: RECRUITING ·Phase: NA

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

NCT00569543 ·Status: COMPLETED

Fertility Preservation in Breast Cancer Patients

NCT02661932 ·Status: COMPLETED ·Phase: PHASE4

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

NCT02598557 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer

NCT01275859 ·Status: COMPLETED ·Phase: PHASE2

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

NCT01077453 ·Status: COMPLETED ·Phase: PHASE1

An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg

NCT00291109 ·Status: COMPLETED

Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)

NCT04568616 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer

NCT00422903 ·Status: COMPLETED ·Phase: PHASE2

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

NCT01896050 ·Status: COMPLETED

Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan

NCT02924584 ·Status: COMPLETED

Prospective Observational Study of Antitumor Activity Correlation Between Hormonal Therapy and Expression miRNA100

NCT02950207 ·Status: UNKNOWN

Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer

NCT01313039 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin

NCT01403688 ·Status: COMPLETED

The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer

NCT01080170 ·Status: COMPLETED

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

NCT00830973 ·Status: COMPLETED

Gene Expression Profiling to Help Define the Need for Neo-Adjuvant Chemotherapy in HR+, HER- Breast Cancer Patients

NCT05666258 ·Status: RECRUITING

Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome

NCT03665077 ·Status: COMPLETED ·Phase: NA

Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors

NCT04651452 ·Status: COMPLETED ·Phase: NA

What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?

NCT04590560 ·Status: RECRUITING ·Phase: NA

Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer

NCT00691678 ·Status: COMPLETED ·Phase: PHASE2

Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)

NCT01129622 ·Status: COMPLETED ·Phase: PHASE2

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

NCT01612871 ·Status: COMPLETED ·Phase: PHASE4

Neoadjuvant Endocrine Therapy in Breast Cancer

NCT03397537 ·Status: COMPLETED ·Phase: PHASE2